Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 500-301-1 | CAS number: 111870-68-9 1 - 6.5 moles propoxylated
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In a study according to OECD 422, oral administration (by gavage) of the analogue, Castor oil, hydrogenated, ethoxylated, to Wistar rats at the doses of 100, 300 and 1000 mg/kg/day for two weeks prior to mating and up to the day before sacrifice inclusive (males) or up to days 13-15 of lactation (females) was well tolerated.
No test item related mortality was recorded during the study.
There were no signs of evident toxicity related to clinical signs, sensory reactivity, grip strength or motor activity. Regarding body weights and food consumption, lower mean values with respect to Control were recorded in males as well as for food consumption in females. However, given the magnitude observed and the fact that the effect in food consumption was also recorded during pre-test, it needs to be considered as a non-adverse effect.
The statistical differences observed in in hematology, coagulation or clinical biochemistry were not considered to be test item related, based on the magnitude and in the absence of a dose relation. These values were within those observed in rats of this strain and age and were there attributed to normal biological variation.
There was no indication of an effect of the substance on T4 levels and there was no evidence of a test-item effect in the histopathology performed on F0 adults.
There were no changes in the macroscopic examination or organ weights that could be attributable to the substance.
Administration of the substance to Wistar rats by oral gavage for 5-8 weeks was not associated with macro/micropathological findings in this study. In the testes, seminiferous tubules were evaluated with respect to their stage in the spermatogenic cycle and the integrity of the various cell types present within the different stages. No cell or stage-specific abnormalities were noted in males treated at 1000 mg/kg.
The NOAEL for repeated dose toxicity was considered to be 1000 mg/kg/day for males and females, taking into account the slight decrease in food consumption and body weights.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: oral, other
- Remarks:
- repeated dose reproduction study OECD 422
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 14 November 2017 to 24 April 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- adopted 29 July 2016
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Crl:CD(SD) rat
- Details on species / strain selection:
- Recognized by international guidelines as a recommended test system
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Strain: Hannover Wistar Rat (HsdHan®:WIST)
- Source: Envigo RMS B.V. Kreuzelweg 53 5961 NM Horst Netherlands
- Females (if applicable) nulliparous and non-pregnant: no data
- Age at study initiation: 10 weeks
- Weight at study initiation: Males: 291-386 g;Females: 197-240 g
- Fasting period before study: no
- Housing:Cages with standard, granulated, S8-15 sawdust bedding (J. Rettenmaier & Söhne)
Premating (maximum 5 animals/cage) Makrolon type-IV cages
Mating (one male and one female/cage) Makrolon type-III cages
Postmating, gestation and lactation (individual) Makrolon type-III cages
- Diet: Pelleted standard Teklad 2014C rat/mouse maintenance diet ad libitum (during lactation Teklad 2018C rat/mouse maintenance diet)
- Water: tap water ad libitum
- Acclimation period: 5 days and 15 days pre-test
ENVIRONMENTAL CONDITIONS
- Temperature: 20-24ºC:
- Humidity: 40-70 %
- Air changes (per hr): 15-20 per hour
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: daily (stored at ambient temperature and in the dark)
1.The necessary quantity of test item was weighed in a single-use container.
2.Small amounts of vehicle were added (approximately 60-70% of the total volume) and mixed with a manual rod. Any lumps were broken up at this point and the final result was an oily solution.
3.The oily solution was transferred to a volumetric flask or graduated measuring cylinder that has been previously moistened with the vehicle. The mortar and the single-use container were rinsed with the vehicle to ensure that there were no remnants of the test item. This vehicle was added to the volumetric container and made up to the mark.
4.When it was necessary to adjust volume, the volume was first added into volumetric vessel and after the remainder was passed at final container. Before the formulation was passed to the final container, it was assured that the formulation was homogenous, and when it was necessary a vortex was used for this purpose.
5.The oily solution was transferred to a suitable container and submitted to stirring for overnight before aliquoting for analysis when necessary.
VEHICLE: propylene glycol
- Concentration in vehicle: 0, 20, 60 and 200 mg/mL
- Amount of vehicle (if gavage): 5 mL/kg bw
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples of each formulation prepared for administration on day 1 and in week 3 were analyzed for achieved concentration of the test item. Prior to initial sampling each day, the formulation was mixed by 20-fold inversion and paddle stirring for minimum of 20 minutes. A representative sample of test formulation (1 mL, accurately weighed) was dissolved using ultrasonic vibration in a suitable volume of propan-2-ol. The extract was diluted, where necessary, using propan-2-ol, to provide a solution containing the substance at an expected concentration within the range 200 µg/mL to 400 µg/mL. The concentration in the final solution was quantified by HPLC using evaporative light scattering detection.
Method:
High performance liquid chromatograph (HPLC): Waters Alliance 2695 separation module and an Alltech Model 3300 ELSD detector
Column: Phenomenex Jupiter C18, 300 Å, 5 µm, 250 × 4.6 mm
Column temperature: 50ºC
Sample temperature: Ambient
Mobile Phase: Propan-2-ol
Flow rate: 1 mL/min
Needle wash: Propan-2-ol
Injection volume: 20 µL
Auto sampler run time: 7 minutes
Empower run time: 6 minutes
Approximate retention time: 3.3 minutes
Detector settings:
Drift tube temperature: 80ºC
Nitrogen flow: 1.5 L/min
Gain: 2
e-SATIN settings:
Environment: 60 Hz
Enable BCD: Off
BCD polarity: positive
Rate: 5 points/second
Description: Channel 1
Scale factor: 1000
Units: mV
Results method validation:
Calibration linearity (range 100-500 ug/mL): r > 0.999 (quadratic relationship)
Specificity: absence of peak for substance in control sample
Precisions calibration (CV 0.97% 100 ug/mL, 0.09% 500 ug/mL)
Accuracy: procedural recovery value of 92.1% (CV=0.83%, n=5) was obtained for 1 mg/mL and 100.2% (CV=0.36%, n=5) was obtained for 200 mg/mL.
LOQ: 1.11 µg/mL and 3.17 µg/mL (3 and 10 times baseline noise)
Preparation analyses:
Homogeneity CV 0.63-2.30% at 20 mg/mL; 0.14-2.78% at 200 mg/mL
Stability over 8 days at 21 °C: 83.4% of initial at 20 mg/mL; 94% of initial at 200 mg/mL
Stability over 15 days at 4 °C: 82.5% of initial at 20 mg/mL; 97.1% of initial at 200 mg/mL
Procedural recovery during test runs: 89.2-103.1% at 20 and 200 mg/mL
Accuracy: 67-107% of nominal 20 mg/mL; 84-106% of nominal at 60 mg/mL; 80-104% of nominal at 200 mg/mL
Day 1 samples at 20 mg/mL were outside the required purity range, as the samples taken in week 3 were within the purity ranges and it concerns the lowest concentration only, this has not affected the study results. - Duration of treatment / exposure:
- Males Two weeks pre-pairing up to necropsy after a minimum of five weeks of treatment (animals were killed in Week 6).
Females Two weeks before pairing, then throughout pairing and gestation until Day 13/15 of lactation. - Frequency of treatment:
- daily
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Remarks:
- measured concentration at day 1 67% of nominal
measured concentration in week 3 107% of nominal - Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Remarks:
- measured concentration 84-107% of nominal
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- measured concentration 80-104% of nominal
- No. of animals per sex per dose:
- 10 males and 10 females
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based on the results of a 2-week dose range finding study
In that study (Hannover Wistar rats dosed at 0 (PEG), 100, 500 or 1000 mg/kg/day) there were no mortalities or substance related clinical signs observed. Food consumption, body weight or water consumption were considered to be unaffected by treatment. There were no substance related macroscopic findings or effects on organ weights.
Under the conditions of this study, the daily oral gavage administration of the substance daily for 14 consecutive days at dose levels up to 1000 mg/kg/day caused no signs of evident toxicity - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: weekly (twice pre-treatment)
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: in a standard arena before treatment commenced and during each week of treatment and for females on Days 0, 7, 14 and 20 after mating and Days 1, 6 and 12 of lactation, detailed physical examination and arena observations
BODY WEIGHT: Yes
- Time schedule for examinations:
F0 males Weekly during pre-treatment
On day 1 and weekly thereafter.
On the day of necrospy.
F0 females Weekly during pre-treatment
On day 1 and weekly thereafter
Days 0, 7, 14 and 20 after mating.
Day 1, 4 and 13 of lactation.
On the day of necropsy.
FOOD CONSUMPTION : Yes
- Time schedule for examinations: weekly except during mating
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at termination
- Anaesthetic used for blood collection: Yes isoflurane
- Animals fasted: Yes 6-8 hours
- How many animals: 5/sex/group
- Parameters checked: Hematocrit (Hct), Hemoglobin concentration (Hb), Erythrocyte count (RBC), Absolute reticulocyte count (Retic), Mean cell hemoglobin (MCH), Mean cell hemoglobin concentration (MCHC)*, Mean cell volume (MCV), Red cell distribution width (RDW), Total leucocyte count (WBC), Differential leucocyte count:, Neutrophils (N), Lymphocytes (L), Eosinophils (E), Basophils (B), Monocytes (M), Large unstained cells (LUC), Platelet count (Plt), Prothrombin time (SPT) and Activated partial thromboplastin time (SAPT)
For samples showing abnormalities in the automated analysis a blood film was analysed microscopically for differential leucocyte count (2 females at 0 mg/kg/day, 1 female at 100 mg/kg/day, two females at 300 mg/kg/day and one female at 1000 mg/kg/day).
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at termination
- Anaesthetic used for blood collection: Yes isoflurane
- Animals fasted: Yes 6-8 hours
- How many animals: 5/sex/group
- Parameters checked: Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Total bilirubin (Bili), Bile acids (Bi Ac), Urea, Creatinine (Creat), Creatine kinasa (CK), Glucose (Gluc), Total cholesterol (Chol), HDL, LDL, Triglycerides (Trig), Sodium (Na), Potassium (K), Chloride (Cl), Calcium (Ca), Inorganic phosphorus (Phos), Total protein (Total Prot), Albumin (Alb), Protein electrophoretogram
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: males in week 5, females at day 7-9 of lactation
- Dose groups that were examined: 5/sex/group
- Battery of functions tested: sensory activity (includes: Blink reflex, Pinna reflex, Iridic light / Pupil closure reflex,
Proprioception (right leg) / push-off (hind legs), Pain response / Tail pinch response, Auditory Startle / hearing reflex, Righting reflex in the air), grip strength (fore-and hind limb) and motor activity(beam crossing over 10 min intervals for 1 hour)
IMMUNOLOGY: Yes
- Time schedule for examinations: at termination
- Anaesthetic used for blood collection: Yes isoflurane
- Animals fasted: Yes 6-8 hours
- How many animals: all adult males
- Dose groups that were examined: all
- Parameters checked: serum samples of the adult males for thyroxine (T4) levels (additional taken samples from all adult females were not further examined)
ESTOUS CYCLE: Yes
vaginal smears using inoculation loops
-For 14 days before treatment (all females including spares); animals that failed to exhibit 4-5 day cycles were not allocated to study.
-Daily from the beginning of treatment period until evidence of mating.
-On day of sacrifice. - Sacrifice and pathology:
- ORGAN WEIGHTS: Yes (see tables)
GROSS PATHOLOGY: Yes (see tables)
Males: after final investigations completed (after 5 weeks of treatment)
Non-pregnant females: Day 25-26 after mating
Pregnant females: Day 14-16 of lactation
HISTOPATHOLOGY: Yes (see tables)
Premature deaths All F0 animals from all groups.
Scheduled kill 5 F0 animals in Groups 1 and 4:
All F0 animals. Abnormalities only. - Other examinations:
- Ovaries: qualitative evaluation of one section from each ovary.
Testes: detailed qualitative examination was made, taking into account the tubular stages of the spermatogenic cycle. The examination was conducted in order to identify treatment-related effects such as missing germ cell layers or types, retained spermatids, multinucleate or apoptotic germ cells and sloughing of spermatogenic cells into the lumen. Any cell- or stage-specificity of testicular findings was noted. - Statistics:
- The following comparisons were performed: Group 1 vs. 2, 3 and 4
For categorical data, the proportion of animals was analyzed for each treated group (as appropriate) versus the control group.
For continuous data, a parametric analysis was performed if Bartlett's test for variance homogeneity was not significant at the 1% level. Treated groups were compared to control using Williams' test, unless there was evidence against a monotonic dose-response when Dunnett's test was performed instead.
A non-parametric analysis was performed if Bartlett's test was still significant at the 1% level following both logarithmic and square-root transformations. Treated groups were compared to control using Shirley's test, unless there was evidence against a monotonic dose response when Steel's test was performed instead.
For organ weight data, analysis of covariance was performed using terminal bodyweight as covariate, unless non-parametric methods were applied. The treatment comparisons were made on adjusted group means in order to allow for differences in bodyweight which might influence the organ weights. A similar analysis was performed for ano-genital distance, using the litter average pup body weight as the covariate.
For estrous cycles an exact one-tailed (upper-tail) Linear-by-linear test was applied to all groups, using scores appropriate to the severity of the observation. If the test was statistically significant (p<0.05), the highest dose group was excluded and the test re-applied. This ‘step-down’ process was repeated until the test was no longer statistically significant (p≥0.05).
Significant differences between the groups compared were expressed at the 5% (p<0.05) or 1% (p<0.01) level. - Clinical signs:
- no effects observed
- Description (incidence and severity):
- no effects in surviving animals
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- 1 male at 300 mg/kg bw was sacrificed for welfare reasons on treatment day 8. It showed the following clinical signs on the day it was sacrificed: reddish nose discharge, prostration, reduced body tone and pallor. Reddish discharge in nose and right dilated kidney pelvis were recorded during necropsy.
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- males: up to 6% decreased between treatment and post-mating day 15 (not considered treatment related)
females: no treatment related effects - Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- males: 89-100% of controls (not considered treatrment related)
females: 67-104% of controls (not considered treatrment related) - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Males: sign decreased leucocytes (lymphocytes) at all doses, no dose response relationship and values within historical control values; decreased APT at 300 and 1000 mg/kg bw (no dose response and non-significant)
Females: increased PT and APT at all doses (no dose response see table); sign increased lymphocytes at 300 mg/kg bw (part of the samples were analysed manually due to errors in the automated assessment)
see tables - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Males: sign increased albumin at all doses, no dose response relationship and values within historical control values; effects on Na, K and Cl at all dose groups (no dose response and within historical controls, see table); decreased bile acids at 100 and 300 mg/kg bw
Females:sign decreased creatine kinase at 300 and 1000 mg/kg bw (no dose response and within historical controls, see table); incidental non-sign increase of bile acids and triglycerides
see tables - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Sensory reactivity observations and grip strength: no treatment related effects
Motor activity: in males and females at 1000 mg/kg/day occasional statistically significant differences compared to controls were observed. Overall effects were non-significant, were considered not to have any toxicological relevancy and were attributed to the normal variability
see table - Immunological findings:
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on the circulating levels of thyroxine (T4) in adult males (see table)
The microscopic examination of thymus, thyroid, adrenal and pituitary glands and the reproductive organs was also unremarkable. - Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- The microscopic examination performed 5-8 weeks after treatment revealed no changes related to the test item at 1000 mg/kg/day. All the histological findings were considered to be incidental.
In the testes, seminiferous tubules were evaluated with respect to their stage in the spermatogenic cycle and the integrity of the various cell types present within the different stages. No cell or stage-specific abnormalities were noted in males treated at 1000 mg/kg/day. - Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- no treatment related effect (oestrus cycle 4-5 days pre-treatment, at termination >90% of females were in diestrous phase)
- Details on results:
- The slight effects on body weight and food consumption are considered to be non-adverse. The behavior of the animals in the arena was not affected by treatment. Sensory reactivity, grip strength and motor activity were also unaffected by treatment. The findings in haematology and clinical chemistry were either incidental or within historical control values. There was no relationship with the applied dose. No macroscopic findings were reported and organ weights did not differ from controls. Hisopatholgical examnination revealed noabnormalities.
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects observed
- Remarks on result:
- other: absence of adverse effects
- Critical effects observed:
- no
- Conclusions:
- In conclusion, oral administration of the substance was well tolerated in the adult animals. In the context of this study, the substance showed no evidence of being an endocrine disruptor.
The no-observed-adverse-effect-level (NOAEL) for systemic toxicity was considered to be 1000 mg/kg/day. - Executive summary:
In this study according to OECD 422, oral administration (by gavage) of the substance to Wistar rats at the doses of 100, 300 and 1000 mg/kg/day for two weeks prior to mating and up to the day before sacrifice inclusive (males) or up to days 13-15 of lactation (females) was well tolerated.
No test item related mortality was recorded during the study.
There were no signs of evident toxicity related to clinical signs, sensory reactivity, grip strength or motor activity. Regarding body weights and food consumption, lower mean values with respect to Control were recorded in males as well as for food consumption in females. However, given the magnitude observed and the fact that the effect in food consumption was also recorded during pre-test, it needs to be considered as a non-adverse effect.
The statistical differences observed in in hematology, coagulation or clinical biochemistry were not considered to be test item related, based on the magnitude and in the absence of a dose relation. These values were within those observed in rats of this strain and age and were there attributed to normal biological variation.
There was no indication of an effect of the substance on T4 levels and there was no evidence of a test-item effect in the histopathology performed on F0 adults.
There were no changes in the macroscopic examination or organ weights that could be attributable to the substance.
Administration of the substance to Wistar rats by oral gavage for 5-8 weeks was not associated with macro/micropathological findings in this study. In the testes, seminiferous tubules were evaluated with respect to their stage in the spermatogenic cycle and the integrity of the various cell types present within the different stages. No cell or stage-specific abnormalities were noted in males treated at 1000 mg/kg.
The NOAEL for repeated dose toxicity was considered to be 1000 mg/kg/day for males and females, taking into account the slight decrease in food consumption and body weights.
Reference
Summary table
Dose (mg/kg bw) |
0 |
|
100 |
|
300 |
|
1000 |
|
Treatment related |
Endpoint |
M |
F |
M |
F |
M |
F |
M |
F |
|
Mortality |
0/10 |
0/10 |
0/10 |
0/10 |
1/10 |
0/10 |
0/10 |
0/10 |
No |
Clinical signs |
NTRE* |
No |
|||||||
Body weight (gain) |
NTRE |
No |
|||||||
Food consumption |
NTRE |
No |
|||||||
Behavioral effects (wk 5 +lact) |
NTRE |
No |
|||||||
Motoractivity (wk 5 + lact) |
|
|
↑(19% ns) |
|
↑(41% ns) |
↑ (24% ns) |
↑ (25% ns) |
↑(13% ns) |
No (no dose-response) |
Estrus cycle (pre-test +PM)# |
NTRE (4-5 days) |
No |
|||||||
Pre-coital interval |
NTRE (1-4 days) |
No |
|||||||
Conception rate (%) |
|
No |
|
100 |
|
80 |
|
90 |
No |
Fertility index (%) |
|
No |
|
100 |
|
80 |
|
90 |
No |
Mating performance |
NTRE (100%) |
No |
|||||||
Gestation length |
NTRE (20-22 days) |
No |
|||||||
Gestation index |
NTRE (100%) |
No |
|||||||
Implementation sites |
|
No |
|
13.6 |
|
14.0 |
|
12.9 |
No |
Litter size (Day 1) |
|
No |
|
11.8 |
|
12.8 |
|
12.9 |
No |
Haematology |
|
|
WBC↓ (29%) Lymph ↓ (34%)
|
PT ↑ (10% ns) APT↑(27% ns) |
WBC↓ (24%) Lymph↓ (28%) APT↓ (13% ns) |
Lymph ↑ (83%)$ PT ↑ (9% ns) APT↑ (22% ns) |
WBC↓ (28%) Lymph ↓ (31%) APT↓ (14% ns) |
PT ↑ (10%) APT↑ (59%) |
No (within historical controls) |
Clinical biochemistry |
|
|
Alb↑ (10%) Na/K/Cl↑ |
Bile ac↑ (137% ns) |
Bile ac↓(27% ns) Alb↑ (17%) Na/K/Cl↑ |
CK↓ (67%)
|
Bile ac↓(32% ns) Alb↑ (17%) Na/K/Cl↑ |
CK↓ (63%) Bile ac ↑ (115% ns) Triglyc↑ (60% ns) |
No (within historical controls) |
Organ weights |
NTRE |
No |
|||||||
Marcoscopy |
NTRE |
No |
|||||||
Histopathology* |
NTRE |
No |
|||||||
Testes |
NTRE |
No |
NTRE= no treatment related effects
↑/↓= significantly increased/decreased
% compared to controls
*in the male that died at 300 mg/kg bw: red nose, reduced body tone, prostrate and whole body pallor on the day of death (day8); unilateral pelvic dilation, in the testes, minimal bilateral tubular vacuolation was seen, along with minimal cell debris and minimally reduced sperm content in the epididymides.
# at termination 90% females in treatment groups were in diestrous phase
$ measured in limited number of animals, but effect stays when manual screening for differential leucocytes is taken into account
Haematology
Group |
WBC (x109/L) Males |
L (x109/L) Males |
SPT (Secs) Females |
SAPT (Secs) Females |
0 mg/kg/day |
7.18 |
5.97 |
14.4 |
23.7 |
100 mg/kg/day |
5.09* |
3.95* |
15.8 |
30.1 |
300 mg/kg/day |
5.44* |
4.27* |
15.7 |
28.9 |
1000 mg/kg/day |
5.14** |
4.13* |
15.8* |
37.6** |
Historical Control Data[1] |
Mean 6.525 Range 3.92 to 9.43 |
Mean 5.554 Range 3.36 to 8.02 |
Mean 16.59 Range 14.7 to 18.8 |
Mean 22.00 Range 13.8 to 41.7 |
[1]In five studies conducted between 2017 and 2018, control rats of the same strain housed in similar environmental conditions.
Clinical Chemistry
Group |
Na (mmol/L) Males |
K (mmol/L) Males |
Cl (mmol/L) Males |
Alb (g/L) Males |
CK (U/L) Females |
0 mg/kg/day |
137 |
3.7 |
95 |
29 |
693 |
100 mg/kg/day |
140 |
3.7 |
98 |
32* |
441 |
300 mg/kg/day |
142* |
4.0 |
98 |
34** |
230* |
1000 mg/kg/day |
141* |
4.1* |
99* |
34** |
257* |
Historical Control Data[1] |
Mean 142.2 Range 135 to 156 |
Mean 3.94 Range 3.4 to 4.8 |
Mean 98.5 Range 94 to 102 |
Mean 34.1 Range 31 to 37 |
Mean 192.9 Range 96 to 414 |
[1]In five studies conducted between 2017 and 2018, control rats of the same strain housed in similar environmental conditions.
Mean serum T4 concentrations (pg/mL)
Group |
|
F0 Males |
Statistical test |
|
Wi |
0 mg/kg/day |
Mean SD N |
50576 6440.4 10 |
100 mg/kg/day |
Mean SD N |
51036 7876.7 10 |
300 mg/kg/day |
Mean SD N |
49972 8775.9 10 |
1000 mg/kg/day |
Mean SD N |
54833 7455.2 10 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- System:
- other: no adverse effects observed
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
No studies on Castor oil, hydrogenated, propoxylated on repeated dose toxicity are available. In view of the structural and physico-chemical similarities between the source and the target chemical, the outcome of the OECD 422 study with Castor oil, hydrogenated, ethoxylated is considered to be representative for the toxicity of the target substance, Castor oil, hydrogenated, propoxylated.
Justification for classification or non-classification
Based on the available information no classification for repeated dose toxicity is necessary according to Regulation (EC) No 1272/2008 (CLP).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.